Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The burden of steroid use in systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Belimumab induces early and sustained resolution of lupus thrombocytopenia.

Lupus science & medicine·2026
Same author

Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy.

Annals of the rheumatic diseases·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026
Same journal

Necrotizing fasciitis of the thigh-a devastating sign of intestinal perforation.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.2K

[Biologics in SLE].

Thomas Karonitsch1, Martin Aringer

  • 1Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich, thomas.karonitsch@meduniwien.ac.at.

Wiener Medizinische Wochenschrift (1946)
|November 21, 2014
PubMed
Summary
This summary is machine-generated.

Biologics offer new hope for treating rheumatic diseases like systemic lupus erythematosus (SLE). Belimumab, an approved biologic, improves quality of life and reduces flares in SLE patients.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.6K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K

Related Experiment Videos

Last Updated: Apr 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.2K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.6K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K

Area of Science:

  • Rheumatology and immunology
  • Pharmacology and therapeutic interventions

Context:

  • Biologic therapies have revolutionized rheumatic disease treatment over the past decade.
  • B-cell depletion has been an off-label strategy for severe systemic lupus erythematosus (SLE).
  • Initial rituximab trials in SLE yielded unexpected negative results, prompting further investigation.

Purpose:

  • To review the evolution of biologic therapies for SLE.
  • To highlight the significance of belimumab's approval and efficacy.
  • To discuss future directions in biologic treatments for SLE.

Summary:

  • Belimumab, an anti-Blys/BAFF antibody, was approved in 2012, marking a new era for SLE treatment.
  • Belimumab has demonstrated efficacy in preventing SLE flares, enabling glucocorticoid dose reduction, and improving patient quality of life.
  • The drug effectively mitigates immune complex-mediated fatigue in SLE patients.

Impact:

  • Belimumab's approval signifies a major advancement in managing SLE.
  • The drug offers significant benefits, including reduced disease activity and improved patient well-being.
  • Ongoing research into novel biologic agents promises further therapeutic options for SLE patients.